United States Biotechnology & Medical Research

Sionna Therapeutics Inc (SION)

Track

Over the past 90 days, Sionna Therapeutics Inc. has seen 14 insider transactions, all of which were sales totaling approximately $96.9 million. Key participants included OrbiMed Advisors LLC and Peter A. Thompson. These transactions occurred following the company's May 2026 earnings report, during a period where the stock price remains near its 52-week high.
Ticker: SION Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Sionna Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 7 Jul 2026
Value US$2,284,128.75 | Price 381.45 | Shares 89,777 (+9.2%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-09 2026-07-07 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
89,777 +9.2%
381.45
US$2,284,129 		89,777 +9.2% 381.45 US$2,284,129
2026-07-09 2026-07-07 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
98,452 +49.2%
470.68
US$1,729,996 		98,452 +49.2% 470.68 US$1,729,996
2026-07-07 2026-07-06 PlS Planned sale
Fitzpatrick Jennifer

Chief Legal Officer

Officer
52,484 -6.7%
288.49
US$3,578,178 		52,484 -6.7% 288.49 US$3,578,178
2026-07-06 2026-07-06 PrS Proposed sale
JENNIFER FITZPATRICK

Officer

Officer
10,250
43.99
US$450,898 		10,250 43.99 US$450,898
2026-07-02 2026-06-30 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
115,844 -4.3%
45.50
US$5,270,902 		115,844 -4.3% 45.50 US$5,270,902
2026-07-02 2026-06-30 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
115,844 -4.3%
45.50
US$5,270,902 		115,844 -4.3% 45.50 US$5,270,902
2026-06-01 2026-05-29 PrS Proposed sale
2.6
OrbiMed Private Investments VIII, LP

Shareholder
210,876
42.82
US$9,029,710 		210,876 42.82 US$9,029,710
2026-05-29 2026-05-29 PrS Proposed sale
2.6
OrbiMed Private Investments VIII, LP

Shareholder
1,082,480
42.80
US$46,330,144 		1,082,480 42.80 US$46,330,144
2026-05-29 2026-05-27 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
101 -0.0%
44.49
US$4,493 		101 -0.0% 44.49 US$4,493
2026-05-29 2026-05-27 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
101 -0.0%
44.49
US$4,493 		101 -0.0% 44.49 US$4,493
2026-05-11 2026-05-11 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
184,639 -6.5%
46.22
US$8,534,015 		184,639 -6.5% 46.22 US$8,534,015
2026-05-11 2026-05-11 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
184,639 -6.5%
46.22
US$8,534,015 		184,639 -6.5% 46.22 US$8,534,015
2026-05-11 2026-05-08 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
59,767 -2.0%
44.58
US$2,664,413 		59,767 -2.0% 44.58 US$2,664,413
2026-05-11 2026-05-08 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
59,767 -2.0%
44.58
US$2,664,413 		59,767 -2.0% 44.58 US$2,664,413
2026-05-11 2026-05-07 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
48,546 -1.6%
44.61
US$2,165,637 		48,546 -1.6% 44.61 US$2,165,637
2026-05-11 2026-05-07 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
48,546 -1.6%
44.61
US$2,165,637 		48,546 -1.6% 44.61 US$2,165,637
2026-04-21 2026-04-18 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
2,948 -0.1%
44.52
US$131,245 		2,948 -0.1% 44.52 US$131,245
2026-04-21 2026-04-18 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
2,948 -0.1%
44.52
US$131,245 		2,948 -0.1% 44.52 US$131,245
2026-04-21 2026-04-17 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
52,397 -1.7%
44.68
US$2,341,098 		52,397 -1.7% 44.68 US$2,341,098
2026-04-21 2026-04-17 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
52,397 -1.7%
44.68
US$2,341,098 		52,397 -1.7% 44.68 US$2,341,098
2026-04-16 2026-04-16 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
226,906 -7.0%
45.34
US$10,287,918 		226,906 -7.0% 45.34 US$10,287,918
2026-04-16 2026-04-16 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
226,906 -7.0%
45.34
US$10,287,918 		226,906 -7.0% 45.34 US$10,287,918
2026-04-16 2026-04-15 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
235,863 -6.8%
44.64
US$10,528,924 		235,863 -6.8% 44.64 US$10,528,924
2026-04-16 2026-04-15 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
235,863 -6.8%
44.64
US$10,528,924 		235,863 -6.8% 44.64 US$10,528,924
2026-04-16 2026-04-14 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
47,814 -1.4%
44.51
US$2,128,201 		47,814 -1.4% 44.51 US$2,128,201
2026-04-16 2026-04-14 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
47,814 -1.4%
44.51
US$2,128,201 		47,814 -1.4% 44.51 US$2,128,201
2026-03-06 2026-03-05 PlS Planned sale
Fitzpatrick Jennifer

Chief Legal Officer

Officer
10,250 -100.0%
33.86
US$347,019 		10,250 -100.0% 33.86 US$347,019
2026-03-05 2026-03-05 PrS Proposed sale
JENNIFER FITZPATRICK

Officer

Officer
10,250
34.57
US$354,342 		10,250 34.57 US$354,342
2026-02-04 2026-02-03 S Sale
3.0
Thompson Peter A.
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-03 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-03 S Sale
3.0
Thompson Peter A.
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-03 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-02 S Sale
3.0
Thompson Peter A.
Non-Executive Director
1,890 -0.1%
44.57
US$84,237 		1,890 -0.1% 44.57 US$84,237
2026-02-04 2026-02-02 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
1,890 -0.1%
44.57
US$84,237 		1,890 -0.1% 44.57 US$84,237
2026-01-26 2026-01-22 S Sale
3.2
TPG GP A, LLC
Large shareholder
250,000 -3.7%
40.00
US$10,000,000 		250,000 -3.7% 40.00 US$10,000,000
2026-01-22 2026-01-22 PrS Proposed sale
Rise Fund Sling, L.P.

Stockholder

Large shareholder
195,667
41.77
US$8,173,011 		195,667 41.77 US$8,173,011
2026-01-22 2026-01-22 PrS Proposed sale
Rise Fund Sling II, L.P.

Stockholder

Large shareholder
54,333
41.77
US$2,269,489 		54,333 41.77 US$2,269,489
2025-12-29 2025-12-24 S Sale
3.0
Thompson Peter A.
Non-Executive Director
33,356 -0.9%
44.55
US$1,486,010 		33,356 -0.9% 44.55 US$1,486,010
2025-12-29 2025-12-24 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
33,356 -0.9%
44.55
US$1,486,010 		33,356 -0.9% 44.55 US$1,486,010
2025-12-19 2025-12-19 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
875 -0.0%
44.49
US$38,929 		875 -0.0% 44.49 US$38,929
2025-12-19 2025-12-19 S Sale
3.0
Thompson Peter A.
Non-Executive Director
875 -0.0%
44.49
US$38,929 		875 -0.0% 44.49 US$38,929
2025-12-19 2025-12-18 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
100 -0.0%
44.49
US$4,449 		100 -0.0% 44.49 US$4,449
2025-12-19 2025-12-18 S Sale
3.0
Thompson Peter A.
Non-Executive Director
100 -0.0%
44.49
US$4,449 		100 -0.0% 44.49 US$4,449
2025-12-19 2025-12-17 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
900 -0.0%
44.50
US$40,050 		900 -0.0% 44.50 US$40,050
2025-12-19 2025-12-17 S Sale
3.0
Thompson Peter A.
Non-Executive Director
900 -0.0%
44.50
US$40,050 		900 -0.0% 44.50 US$40,050
2025-12-09 2025-12-05 PlS Planned sale
Fitzpatrick Jennifer

Chief Legal Officer

Officer
10,250 -100.0%
40.52
US$415,330 		10,250 -100.0% 40.52 US$415,330
2025-12-05 2025-12-05 PrS Proposed sale
JENNIFER R FITZPATRICK

Officer

Officer
10,250
40.88
US$419,020 		10,250 40.88 US$419,020
2025-11-26 2025-11-26 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
1,600 -0.0%
44.49
US$71,184 		1,600 -0.0% 44.49 US$71,184
2025-11-26 2025-11-26 S Sale
3.0
Thompson Peter A.
Non-Executive Director
1,600 -0.0%
44.49
US$71,184 		1,600 -0.0% 44.49 US$71,184
2025-11-26 2025-11-25 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
11,890 -0.3%
44.60
US$530,294 		11,890 -0.3% 44.60 US$530,294
2025-11-26 2025-11-25 S Sale
3.0
Thompson Peter A.
Non-Executive Director
11,890 -0.3%
44.60
US$530,294 		11,890 -0.3% 44.60 US$530,294
2025-11-26 2025-11-24 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
94,583 -2.6%
44.54
US$4,212,727 		94,583 -2.6% 44.54 US$4,212,727
2025-11-26 2025-11-24 S Sale
3.0
Thompson Peter A.
Non-Executive Director
94,583 -2.6%
44.54
US$4,212,727 		94,583 -2.6% 44.54 US$4,212,727
2025-11-24 2025-11-24 PrS Proposed sale
2.6
OrbiMed Private Investments VIII, LP

Shareholder
1,047,770
44.38
US$46,500,033 		1,047,770 44.38 US$46,500,033
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
7,609 -4.6%
39.50
US$300,556 		7,609 -4.6% 39.50 US$300,556
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
6,440 -0.3%
39.50
US$254,380 		6,440 -0.3% 39.50 US$254,380
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
9,924 -1.5%
39.50
US$391,998 		9,924 -1.5% 39.50 US$391,998
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,210 -0.0%
39.50
US$47,795 		1,210 -0.0% 39.50 US$47,795
2025-11-21 2025-11-21 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
6,440
43.66
US$281,170 		6,440 43.66 US$281,170
2025-11-21 2025-11-21 PrS Proposed sale
RA Capital Healthcare Fund LP

Director; 10% Stockholder

Non-Executive Director Large shareholder
1,210
43.66
US$52,829 		1,210 43.66 US$52,829
2025-11-21 2025-11-21 PrS Proposed sale
RA Capital Nexus Fund, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
9,924
43.66
US$433,282 		9,924 43.66 US$433,282
2025-11-21 2025-11-21 PrS Proposed sale
BLACKWELL PARTNERS LLC - SERIES A

Director; 10% Stockholder

Non-Executive Director Large shareholder
7,609
43.66
US$332,209 		7,609 43.66 US$332,209
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
604 -0.4%
40.50
US$24,462 		604 -0.4% 40.50 US$24,462
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
512 -0.0%
40.50
US$20,736 		512 -0.0% 40.50 US$20,736
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
788 -0.1%
40.50
US$31,914 		788 -0.1% 40.50 US$31,914
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
96 -0.0%
40.50
US$3,888 		96 -0.0% 40.50 US$3,888
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
947 -0.6%
39.89
US$37,776 		947 -0.6% 39.89 US$37,776
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
801 -0.0%
39.89
US$31,952 		801 -0.0% 39.89 US$31,952
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,235 -0.2%
39.89
US$49,264 		1,235 -0.2% 39.89 US$49,264
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
150 -0.0%
39.89
US$5,984 		150 -0.0% 39.89 US$5,984
2025-11-20 2025-11-20 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
1,313
38.94
US$51,128 		1,313 38.94 US$51,128
2025-11-20 2025-11-20 PrS Proposed sale
RA Capital Nexus Fund, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
2,023
38.94
US$78,776 		2,023 38.94 US$78,776
2025-11-20 2025-11-20 PrS Proposed sale
RA Capital Healthcare Fund LP

Director; 10% Stockholder

Non-Executive Director Large shareholder
246
38.94
US$9,579 		246 38.94 US$9,579
2025-11-20 2025-11-20 PrS Proposed sale
BLACKWELL PARTNERS LLC - SERIES A

Director; 10% Stockholder

Non-Executive Director Large shareholder
1,551
38.94
US$60,396 		1,551 38.94 US$60,396
2025-11-19 2025-11-19 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
12,134
38.41
US$466,066 		12,134 38.41 US$466,066
Explore more

More insider trading research around Sionna Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America